Dorian LeBlanc: Yes, absolutely. The one other piece maybe to think about on cash runway is we do have a number of receivables on the books not trade receivables, but particularly the tax receivables. So, we have $25.2 million at the end of Q2 in tax receivables largely from UK R&D tax credits. We do anticipate that coming through before the end of the year and contributing significantly to liquidity. And then we will work on where we are with Pharmakon in future amendments and working through the overall liquidity for the fourth quarter, but draw of $16 million will certainly take us through September.
Mark Massaro: Last question for me. Can you maybe explain what the measurement of the covenant and the Ninth Amendment? What that pertains to? Just, I’m trying to get a sense for some of the details around the statement about the measurement there.
Dorian LeBlanc: So, right now, during the term of the Ninth Amendment, the only covenant that applies is the minimum liquidity covenant of $5 million. We have no other covenants that are in effect when the Ninth Amendment ends. Then we would return to the original revenue covenants that had us, that were set during the pandemic. And therefore, outdated would need to be negotiated with a lender.
Ron Zwanziger: Mark, I’ll just add to the first question about respiratory and revenues. So, you made the comment that Q3 tends to be the weak in respiratory tends to be the weaker one, but actually, Q2 tends to often be the weaker one than Q3 because Q3 sometimes gets the initial stocking orders for the fourth quarter flu season, but obviously, because of the ITAP program, we don’t know where we stand with the U.S. that complicates matters. But then there’s also the general complication of the flu season in Europe and Japan as well, making any comments very particularly tricky.
Operator: Thank you. I am currently showing no further questions at this time. I’d like to turn the conference back to Mr. Ron Zwanziger for closing remarks.
Ron Zwanziger : Okay, thanks. So, our transition to a non-COVID product portfolio continues to progress. Especially with the commercial launches of the HbA1c test and the NT-proBNP test on our platform. Customer responses continue to be positive, supported by external clinical validations. So again, bringing together multiple assays on a single easy-to-use instrument with laboratory equivalent performance and a low cost of ownership is enabling a transformation in community-based care. Now, in parallel to the focus on our business and test expansion, we continue to work with various strategic advisors on the previously disclosed strategic review of our business with the support of our senior lender, which we’re engaged in discussions with them about the terms of the loan agreement as amended to date, including the covenants in the Ninth Amendment, which is scheduled to be measured on September the first.
While there’d be no guarantees about the outcome of the strategic review process, or our ability to renegotiate terms of the loan agreement with our senior lender. We remain committed to preserving and protecting the value of our business while we continue to aim to deliver on product expansion into the U.S. and commercial growth of our approved tests internationally. Thank you for your time and for your support of LumiraDx. Bye.
Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.
